Randomized, controlled, multi-center trial: Comparing the safety and efficacy of DA-9701 and itopride hydrochloride in patients with functional dyspepsia

Myung Gyu Choi, Poong Lyul Rhee, Hyojin Park, Oh Young Lee, Kwang Jae Lee, Suck Chei Choi, Sang Young Seol, Hoon-Jai Chun, Jong Sun Rew, Dong Ho Lee, Geun Am Song, Hwoon Yong Jung, Hyung Yong Jeong, In Kyung Sung, Joon Seong Lee, Soo Teik Lee, Sung Kook Kim, Yong Woon Shin

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background/Aims Therapies of functional dyspepsia (FD) are limited. DA-9701 is a novel prokinetic agent formulated with Pharbitis semen and Corydalis Tuber. We aimed to assess the efficacy of DA-9701 compared with itopride in FD patients. Methods Patients with FD randomly received either itopride 50 mg or DA-9701 30 mg t.i.d after a 2-week baseline period. After 4 weeks of treatment, 2 primary efficacy endpoints were analyzed: the change from baseline in composite score of the 8 dyspeptic symptoms and the overall treatment effect. Impact on patients' quality of life was assessed using the Nepean Dyspepsia Index (NDI) questionnaire. Results We randomly assigned 464 patients with 455 having outcome data. The difference of the composite score change of the 8 symptoms between the 2 groups was 0.62, indicating that DA-9701 was not inferior to itopride. The overall treatment effect response rate was not different between the groups. When responder was defined as ≥ 5 of the 7 Likert scale, responder rates were 37% of DA-9701 and 36% of itopride group. Patients receiving DA-9701 experienced similar mean percentage of days with adequate relief during the 4-week treatment period compared with those receiving itopride (56.8% vs 59.1%). Both drugs increased the NDI score of 5 domains without any difference in change of the NDI score between the groups. The safety profile of both drugs was comparable. Conclusions DA-9701 significantly improves symptoms in patients with FD. DA-9701 showed non-inferior efficacy to itopride with comparable safety.

Original languageEnglish
Pages (from-to)414-422
Number of pages9
JournalJournal of Neurogastroenterology and Motility
Volume21
Issue number3
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Dyspepsia
Safety
Corydalis
Therapeutics
DA-9701
itopride
Semen
Pharmaceutical Preparations
Quality of Life

Keywords

  • Clinical trial
  • DA-9701
  • Functional dyspepsia
  • Itopride

ASJC Scopus subject areas

  • Clinical Neurology
  • Gastroenterology

Cite this

Randomized, controlled, multi-center trial : Comparing the safety and efficacy of DA-9701 and itopride hydrochloride in patients with functional dyspepsia. / Choi, Myung Gyu; Rhee, Poong Lyul; Park, Hyojin; Lee, Oh Young; Lee, Kwang Jae; Choi, Suck Chei; Seol, Sang Young; Chun, Hoon-Jai; Rew, Jong Sun; Lee, Dong Ho; Song, Geun Am; Jung, Hwoon Yong; Jeong, Hyung Yong; Sung, In Kyung; Lee, Joon Seong; Lee, Soo Teik; Kim, Sung Kook; Shin, Yong Woon.

In: Journal of Neurogastroenterology and Motility, Vol. 21, No. 3, 01.01.2015, p. 414-422.

Research output: Contribution to journalArticle

Choi, MG, Rhee, PL, Park, H, Lee, OY, Lee, KJ, Choi, SC, Seol, SY, Chun, H-J, Rew, JS, Lee, DH, Song, GA, Jung, HY, Jeong, HY, Sung, IK, Lee, JS, Lee, ST, Kim, SK & Shin, YW 2015, 'Randomized, controlled, multi-center trial: Comparing the safety and efficacy of DA-9701 and itopride hydrochloride in patients with functional dyspepsia', Journal of Neurogastroenterology and Motility, vol. 21, no. 3, pp. 414-422. https://doi.org/10.5056/jnm14117
Choi, Myung Gyu ; Rhee, Poong Lyul ; Park, Hyojin ; Lee, Oh Young ; Lee, Kwang Jae ; Choi, Suck Chei ; Seol, Sang Young ; Chun, Hoon-Jai ; Rew, Jong Sun ; Lee, Dong Ho ; Song, Geun Am ; Jung, Hwoon Yong ; Jeong, Hyung Yong ; Sung, In Kyung ; Lee, Joon Seong ; Lee, Soo Teik ; Kim, Sung Kook ; Shin, Yong Woon. / Randomized, controlled, multi-center trial : Comparing the safety and efficacy of DA-9701 and itopride hydrochloride in patients with functional dyspepsia. In: Journal of Neurogastroenterology and Motility. 2015 ; Vol. 21, No. 3. pp. 414-422.
@article{36954f880b114354aa88642a7994b0d5,
title = "Randomized, controlled, multi-center trial: Comparing the safety and efficacy of DA-9701 and itopride hydrochloride in patients with functional dyspepsia",
abstract = "Background/Aims Therapies of functional dyspepsia (FD) are limited. DA-9701 is a novel prokinetic agent formulated with Pharbitis semen and Corydalis Tuber. We aimed to assess the efficacy of DA-9701 compared with itopride in FD patients. Methods Patients with FD randomly received either itopride 50 mg or DA-9701 30 mg t.i.d after a 2-week baseline period. After 4 weeks of treatment, 2 primary efficacy endpoints were analyzed: the change from baseline in composite score of the 8 dyspeptic symptoms and the overall treatment effect. Impact on patients' quality of life was assessed using the Nepean Dyspepsia Index (NDI) questionnaire. Results We randomly assigned 464 patients with 455 having outcome data. The difference of the composite score change of the 8 symptoms between the 2 groups was 0.62, indicating that DA-9701 was not inferior to itopride. The overall treatment effect response rate was not different between the groups. When responder was defined as ≥ 5 of the 7 Likert scale, responder rates were 37{\%} of DA-9701 and 36{\%} of itopride group. Patients receiving DA-9701 experienced similar mean percentage of days with adequate relief during the 4-week treatment period compared with those receiving itopride (56.8{\%} vs 59.1{\%}). Both drugs increased the NDI score of 5 domains without any difference in change of the NDI score between the groups. The safety profile of both drugs was comparable. Conclusions DA-9701 significantly improves symptoms in patients with FD. DA-9701 showed non-inferior efficacy to itopride with comparable safety.",
keywords = "Clinical trial, DA-9701, Functional dyspepsia, Itopride",
author = "Choi, {Myung Gyu} and Rhee, {Poong Lyul} and Hyojin Park and Lee, {Oh Young} and Lee, {Kwang Jae} and Choi, {Suck Chei} and Seol, {Sang Young} and Hoon-Jai Chun and Rew, {Jong Sun} and Lee, {Dong Ho} and Song, {Geun Am} and Jung, {Hwoon Yong} and Jeong, {Hyung Yong} and Sung, {In Kyung} and Lee, {Joon Seong} and Lee, {Soo Teik} and Kim, {Sung Kook} and Shin, {Yong Woon}",
year = "2015",
month = "1",
day = "1",
doi = "10.5056/jnm14117",
language = "English",
volume = "21",
pages = "414--422",
journal = "Journal of Neurogastroenterology and Motility",
issn = "2093-0879",
publisher = "Korean Society of Neurogastroenterology and Motility",
number = "3",

}

TY - JOUR

T1 - Randomized, controlled, multi-center trial

T2 - Comparing the safety and efficacy of DA-9701 and itopride hydrochloride in patients with functional dyspepsia

AU - Choi, Myung Gyu

AU - Rhee, Poong Lyul

AU - Park, Hyojin

AU - Lee, Oh Young

AU - Lee, Kwang Jae

AU - Choi, Suck Chei

AU - Seol, Sang Young

AU - Chun, Hoon-Jai

AU - Rew, Jong Sun

AU - Lee, Dong Ho

AU - Song, Geun Am

AU - Jung, Hwoon Yong

AU - Jeong, Hyung Yong

AU - Sung, In Kyung

AU - Lee, Joon Seong

AU - Lee, Soo Teik

AU - Kim, Sung Kook

AU - Shin, Yong Woon

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background/Aims Therapies of functional dyspepsia (FD) are limited. DA-9701 is a novel prokinetic agent formulated with Pharbitis semen and Corydalis Tuber. We aimed to assess the efficacy of DA-9701 compared with itopride in FD patients. Methods Patients with FD randomly received either itopride 50 mg or DA-9701 30 mg t.i.d after a 2-week baseline period. After 4 weeks of treatment, 2 primary efficacy endpoints were analyzed: the change from baseline in composite score of the 8 dyspeptic symptoms and the overall treatment effect. Impact on patients' quality of life was assessed using the Nepean Dyspepsia Index (NDI) questionnaire. Results We randomly assigned 464 patients with 455 having outcome data. The difference of the composite score change of the 8 symptoms between the 2 groups was 0.62, indicating that DA-9701 was not inferior to itopride. The overall treatment effect response rate was not different between the groups. When responder was defined as ≥ 5 of the 7 Likert scale, responder rates were 37% of DA-9701 and 36% of itopride group. Patients receiving DA-9701 experienced similar mean percentage of days with adequate relief during the 4-week treatment period compared with those receiving itopride (56.8% vs 59.1%). Both drugs increased the NDI score of 5 domains without any difference in change of the NDI score between the groups. The safety profile of both drugs was comparable. Conclusions DA-9701 significantly improves symptoms in patients with FD. DA-9701 showed non-inferior efficacy to itopride with comparable safety.

AB - Background/Aims Therapies of functional dyspepsia (FD) are limited. DA-9701 is a novel prokinetic agent formulated with Pharbitis semen and Corydalis Tuber. We aimed to assess the efficacy of DA-9701 compared with itopride in FD patients. Methods Patients with FD randomly received either itopride 50 mg or DA-9701 30 mg t.i.d after a 2-week baseline period. After 4 weeks of treatment, 2 primary efficacy endpoints were analyzed: the change from baseline in composite score of the 8 dyspeptic symptoms and the overall treatment effect. Impact on patients' quality of life was assessed using the Nepean Dyspepsia Index (NDI) questionnaire. Results We randomly assigned 464 patients with 455 having outcome data. The difference of the composite score change of the 8 symptoms between the 2 groups was 0.62, indicating that DA-9701 was not inferior to itopride. The overall treatment effect response rate was not different between the groups. When responder was defined as ≥ 5 of the 7 Likert scale, responder rates were 37% of DA-9701 and 36% of itopride group. Patients receiving DA-9701 experienced similar mean percentage of days with adequate relief during the 4-week treatment period compared with those receiving itopride (56.8% vs 59.1%). Both drugs increased the NDI score of 5 domains without any difference in change of the NDI score between the groups. The safety profile of both drugs was comparable. Conclusions DA-9701 significantly improves symptoms in patients with FD. DA-9701 showed non-inferior efficacy to itopride with comparable safety.

KW - Clinical trial

KW - DA-9701

KW - Functional dyspepsia

KW - Itopride

UR - http://www.scopus.com/inward/record.url?scp=84934754662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934754662&partnerID=8YFLogxK

U2 - 10.5056/jnm14117

DO - 10.5056/jnm14117

M3 - Article

AN - SCOPUS:84934754662

VL - 21

SP - 414

EP - 422

JO - Journal of Neurogastroenterology and Motility

JF - Journal of Neurogastroenterology and Motility

SN - 2093-0879

IS - 3

ER -